# Lecture 03: Rheumatoid Arthritis ## Unit 2.10: Musculoskeletal and Dermatology --- ## Learning Objectives By the end of this lecture, students will be able to: 1. Describe the epidemiology and pathogenesis of rheumatoid arthritis 2. Explain the clinical features and diagnostic criteria 3. Describe the laboratory and imaging findings 4. Explain the treatment approach including DMARDs 5. Describe the extra-articular manifestations 6. Explain the monitoring and prognosis of rheumatoid arthritis --- ## Lecture Outline ### I. Overview and Epidemiology of Rheumatoid Arthritis Rheumatoid arthritis is a chronic, systemic autoimmune disease characterized by inflammatory synovitis that primarily targets the synovial membrane of diarthrodial joints, leading to progressive joint destruction if left untreated. The disease manifests as a symmetric polyarthritis predominantly affecting the small joints of the hands and feet, though virtually any synovial joint may become involved. The course is typically one of chronic inflammation with periods of exacerbation and relative quiescence, though modern treatment has significantly altered the natural history. Beyond articular manifestations, rheumatoid arthritis is a systemic disease with extra-articular features affecting multiple organ systems and contributing to increased morbidity and mortality. The prevalence of rheumatoid arthritis is approximately 0.5-1% worldwide, affecting an estimated 1.5 million adults in the United States alone. Women are affected approximately three times more frequently than men, with this female predominance suggesting hormonal influences on disease susceptibility and expression. Peak incidence occurs between ages 30 and 50 years, though disease can develop at any age, including juvenile-onset forms. The incidence in women increases with age until approximately 80 years, while in men it continues to rise throughout life. Geographic and ethnic variations exist, with some Native American populations demonstrating particularly high prevalence and certain Asian populations having somewhat lower rates. Genetic factors contribute substantially to rheumatoid arthritis susceptibility, with heritability estimated at approximately 60%. The strongest genetic association is with HLA-DR4 and related alleles sharing the "shared epitope," a conserved amino acid sequence (QKRAA or similar) in the third hypervariable region of the HLA-DRB1 gene that may present arthritogenic peptides to T cells or influence T cell repertoire development. Multiple non-HLA genetic polymorphisms contribute smaller effects, including PTPN22 (encoding a protein tyrosine phosphatase regulating T cell activation), STAT4 (involved in cytokine signaling), and numerous other loci identified through genome-wide association studies. The polygenic nature of susceptibility implies that multiple genetic variants interact with environmental factors to determine disease risk. Environmental factors interact with genetic susceptibility to trigger disease development, with cigarette smoking representing the strongest and best-established modifiable risk factor. Smoking increases rheumatoid arthritis risk two to three-fold, with greater risk associated with heavier smoking and longer duration, and the association is particularly strong for anti-citrullinated protein antibody (ACPA)-positive disease. The mechanistic link may involve citrullination of proteins in inflamed lung tissue, generating neoantigens that trigger autoimmunity in genetically susceptible individuals. Periodontal disease and infection with Porphyromonas gingivalis, which expresses a citrullinating enzyme, have been associated with ACPA development and rheumatoid arthritis risk. Other potential environmental factors include silica dust exposure, obesity, and possibly viral infections, though causal relationships remain to be definitively established. Panel A: World map showing rheumatoid arthritis prevalence rates by region, with higher rates indicated in Native American populations and varying rates across different geographic areas. Panel B: Graph demonstrating female predominance with approximately 3:1 female to male ratio and age-specific incidence curves showing peak onset between 30-50 years in women. Panel C: Diagram of HLA-DR4 and shared epitope concept showing the MHC class II molecule presenting a citrullinated peptide to the T cell receptor, illustrating the genetic predisposition mechanism. Panel D: Risk factor diagram showing modifiable factors (smoking, periodontal disease, obesity) and non-modifiable factors (genetics, sex, age) contributing to rheumatoid arthritis development. --- ### II. Pathophysiology of Rheumatoid Arthritis The pathogenesis of rheumatoid arthritis involves a complex interplay of genetic susceptibility, environmental triggers, and immune dysregulation culminating in chronic synovial inflammation and joint destruction. The initiation phase may begin years before clinical symptoms, during which autoantibodies including rheumatoid factor and anti-citrullinated protein antibodies develop in genetically susceptible individuals exposed to environmental triggers. Citrullination, the post-translational conversion of arginine to citrulline by peptidylarginine deiminase enzymes, creates neoantigens that may break immune tolerance. This pre-clinical autoimmunity phase represents a potential window for preventive intervention, though reliable methods to identify at-risk individuals and effective preventive strategies remain under investigation. Synovial inflammation in established rheumatoid arthritis involves the coordinated action of multiple immune cell populations within the synovial membrane. CD4+ T cells, predominantly of Th1 and Th17 phenotypes, infiltrate the synovium and produce pro-inflammatory cytokines that activate other cell types and perpetuate inflammation. B cells contribute through autoantibody production, antigen presentation, and cytokine secretion. Macrophages are abundant in rheumatoid synovium and serve as major producers of the key inflammatory cytokines TNF-alpha, IL-1, and IL-6. Fibroblast-like synoviocytes, normally quiescent cells lining the synovial membrane, become activated and proliferate, developing an aggressive, invasive phenotype that directly contributes to cartilage and bone destruction. Dendritic cells present antigens and sustain T cell activation within the inflamed synovium. The cytokine network within the rheumatoid synovium drives inflammation and tissue destruction through interconnected signaling cascades. Tumor necrosis factor-alpha (TNF-alpha) occupies a central position in this network, stimulating production of other cytokines, activating endothelial cells to facilitate leukocyte recruitment, and promoting osteoclast differentiation leading to bone erosion. Interleukin-1 (IL-1) potently stimulates cartilage destruction through induction of matrix metalloproteinases and inhibition of cartilage matrix synthesis. Interleukin-6 (IL-6) mediates systemic inflammatory effects including acute phase response, anemia, and fatigue, while also contributing locally to synovitis. Interleukin-17 produced by Th17 cells promotes osteoclast activation and bone erosion. Receptor activator of nuclear factor kappa-B ligand (RANKL) expressed by synovial fibroblasts and T cells directly stimulates osteoclast differentiation and activation. The destructive phase of rheumatoid arthritis results from the formation of pannus, a highly vascularized, invasive synovial tissue that directly invades cartilage and bone at the joint margins. Fibroblast-like synoviocytes within the pannus express matrix metalloproteinases and other enzymes that degrade cartilage matrix, while osteoclasts at the pannus-bone interface mediate bone erosion. Erosions characteristically occur at the bare areas where bone is not covered by cartilage and is exposed to the synovial environment. Cartilage destruction results from both direct enzymatic degradation and impaired chondrocyte function in the inflammatory milieu. Progressive destruction leads to loss of joint space, subluxation, deformity, and ultimately functional disability if inflammation is not controlled. Panel A: Timeline diagram showing the progression from genetic susceptibility through environmental trigger exposure, pre-clinical autoimmunity (ACPA development), to clinical disease onset, illustrating the concept of a "window of opportunity" for intervention. Panel B: Cross-section of inflamed rheumatoid synovium showing infiltrating immune cells (T cells, B cells, macrophages), proliferating fibroblast-like synoviocytes, new blood vessel formation, and pannus tissue invading cartilage at the joint margin. Panel C: Cytokine network diagram showing TNF-alpha at the center with connections to IL-1, IL-6, IL-17, and RANKL, and their downstream effects on inflammation, cartilage destruction, and bone erosion. Panel D: Histological comparison of normal synovium (thin, one to two cell layers) versus rheumatoid synovium (hyperplastic, multiple cell layers with immune cell infiltration and pannus formation). --- ### III. Articular Clinical Features The articular manifestations of rheumatoid arthritis characteristically follow a pattern of symmetric polyarthritis predominantly affecting the small joints of the hands and feet, though large joints may also be involved as disease progresses. Symmetry refers to bilateral involvement of the same joint regions, though absolute mirror-image symmetry is not required. The metacarpophalangeal (MCP), proximal interphalangeal (PIP), and wrist joints are most commonly affected in the hands, while the metatarsophalangeal (MTP) joints are frequently involved in the feet. Importantly, the distal interphalangeal (DIP) joints and thoracolumbar spine are characteristically spared in rheumatoid arthritis, helping to distinguish it from osteoarthritis and spondyloarthropathies. The cervical spine, particularly the atlantoaxial joint, can be affected with potentially serious consequences including instability and myelopathy. Inflammatory joint symptoms differ fundamentally from the mechanical symptoms of osteoarthritis, with morning stiffness representing a key distinguishing feature. Patients with rheumatoid arthritis typically experience prolonged morning stiffness lasting 60 minutes or more, often several hours, reflecting overnight accumulation of inflammatory fluid within joints that dissipates with activity. By contrast, osteoarthritis typically produces stiffness lasting less than 30 minutes. Joint pain in rheumatoid arthritis may be worse with rest and improve with activity, opposite to the pattern in osteoarthritis. Swelling results from synovial hypertrophy and effusion rather than bony enlargement. Fatigue is often prominent and may be disproportionate to the degree of joint involvement, reflecting the systemic nature of the inflammatory process. Physical examination in active rheumatoid arthritis reveals signs of synovitis including swelling, warmth, and tenderness at affected joints. Synovitis produces a characteristic boggy or doughy swelling from synovial proliferation, distinguishable from the firm bony enlargement of osteoarthritis. Warmth over inflamed joints reflects increased blood flow to the synovium. Tenderness on palpation or with motion indicates active inflammation. Range of motion may be limited by pain, swelling, and eventually by structural damage. Early in disease, findings may be subtle and intermittent, while established disease demonstrates more persistent signs. Careful examination of all joints, including the feet which patients may not spontaneously mention, is essential for accurate assessment. Characteristic hand deformities develop in inadequately controlled rheumatoid arthritis, reflecting the cumulative effects of chronic inflammation on periarticular structures. Ulnar deviation at the MCP joints results from weakening of collateral ligaments and extensor tendons combined with the natural ulnar pull of finger flexors. Swan neck deformity features hyperextension at the PIP joint with flexion at the DIP joint, caused by volar plate laxity and dorsal subluxation of lateral bands. Boutonniere deformity shows the opposite pattern with PIP flexion and DIP hyperextension, resulting from central slip rupture and lateral band displacement. Z-thumb deformity involves MCP flexion with IP hyperextension. The piano key sign indicates ulnar styloid instability. These deformities develop over years of uncontrolled disease and are less common with modern treatment approaches that achieve early disease control. Panel A: Diagram showing the characteristic joint distribution in rheumatoid arthritis with affected joints highlighted (MCPs, PIPs, wrists, MTPs, larger joints) and spared joints indicated (DIPs, thoracolumbar spine), with symmetric bilateral involvement emphasized. Panel B: Clinical photographs comparing synovitis in rheumatoid arthritis (boggy soft tissue swelling at MCPs and wrists with warmth) versus osteoarthritis (bony enlargement at DIPs and PIPs with Heberden and Bouchard nodes). Panel C: Illustrations of hand deformities showing ulnar deviation at MCPs, swan neck deformity (PIP hyperextension, DIP flexion), boutonniere deformity (PIP flexion, DIP hyperextension), and Z-thumb deformity with anatomical explanations for each. Panel D: Timeline showing progression from early synovitis (reversible with treatment) through established disease with erosions to deforming arthritis, emphasizing the importance of early intervention. --- ### IV. Extra-Articular Manifestations Rheumatoid nodules represent the most common extra-articular manifestation, occurring in 20-30% of patients with rheumatoid arthritis, almost exclusively in those who are seropositive for rheumatoid factor. These subcutaneous nodules develop at sites of pressure or friction, most commonly over the olecranon, extensor surface of the forearm, and other bony prominences, though they may occur in virtually any location including visceral organs. Histologically, rheumatoid nodules feature a central zone of fibrinoid necrosis surrounded by palisading macrophages and an outer layer of granulation tissue. While typically asymptomatic, nodules may cause discomfort at pressure points, become infected, or rarely ulcerate. Paradoxically, methotrexate may induce accelerated nodulosis in some patients despite improving other disease manifestations. Pulmonary involvement represents a major cause of morbidity and mortality in rheumatoid arthritis, with interstitial lung disease (ILD) being the most clinically significant manifestation. Rheumatoid ILD most commonly presents as usual interstitial pneumonia (UIP) or nonspecific interstitial pneumonia (NSIP) patterns on high-resolution CT, with the former carrying a worse prognosis. Symptoms include progressive dyspnea and nonproductive cough, though disease may be subclinical and detected only on screening. Pleural disease including effusions and pleuritis occurs, with rheumatoid pleural effusions characteristically demonstrating very low glucose and high lactate dehydrogenase levels. Pulmonary nodules resembling subcutaneous nodules may develop and can cavitate or become infected. Caplan syndrome describes the association of rheumatoid nodules with coal workers' pneumoconiosis. Bronchiectasis and airway disease also occur with increased frequency. Cardiovascular disease represents the leading cause of mortality in rheumatoid arthritis, with patients experiencing accelerated atherosclerosis and increased risk of myocardial infarction, heart failure, and cardiovascular death compared to the general population. The increased risk is only partially explained by traditional cardiovascular risk factors and reflects the contribution of systemic inflammation to atherosclerosis pathogenesis. Inflammatory cytokines promote endothelial dysfunction, oxidative stress, and foam cell formation within arterial plaques. Pericarditis occurs in rheumatoid arthritis, usually as asymptomatic pericardial effusion detectable on echocardiography, though symptomatic pericarditis and rarely constrictive pericarditis may develop. Myocarditis and conduction abnormalities are uncommon. Rheumatoid vasculitis, now rare with modern treatment, affects small and medium vessels and may involve the heart. Additional extra-articular manifestations reflect the systemic inflammatory nature of rheumatoid arthritis. Ocular involvement includes episcleritis (superficial, typically benign), scleritis (deeper, potentially vision-threatening), and keratoconjunctivitis sicca (dry eyes from secondary Sjogren syndrome). Hematologic abnormalities are common, with anemia of chronic disease (normocytic, normochromic with low iron but elevated ferritin) occurring in most patients with active disease. Felty syndrome, the triad of rheumatoid arthritis, splenomegaly, and neutropenia, is rare but predisposes to serious infections. Neurological manifestations include entrapment neuropathies (particularly carpal tunnel syndrome from synovitis), cervical myelopathy from atlantoaxial instability, and peripheral neuropathy from vasculitis. Renal involvement may result from medications (NSAIDs, cyclosporine) or rarely amyloidosis in long-standing disease. Panel A: Cross-section diagram of a rheumatoid nodule showing central fibrinoid necrosis, surrounding palisading macrophages, and outer granulation tissue layer, with a clinical photograph of subcutaneous nodules over the extensor forearm. Panel B: High-resolution CT scan images comparing usual interstitial pneumonia pattern (honeycombing, traction bronchiectasis at lung bases) and rheumatoid pleural effusion, with pulmonary function test findings indicated. Panel C: Diagram illustrating the relationship between systemic inflammation in rheumatoid arthritis and accelerated atherosclerosis, showing elevated inflammatory cytokines promoting endothelial dysfunction, oxidative stress, and plaque formation. Panel D: Overview of extra-articular manifestations by organ system including ocular (scleritis, dry eyes), hematologic (anemia, Felty syndrome), neurologic (carpal tunnel, cervical myelopathy), and cutaneous (nodules, vasculitis) with approximate frequencies. --- ### V. Diagnosis and Classification Criteria The 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria were developed to identify patients with early inflammatory arthritis who would benefit from early disease-modifying therapy. The criteria apply to patients with at least one joint with definite clinical synovitis not better explained by another diagnosis. A score of 6 or more out of 10 possible points classifies a patient as having definite rheumatoid arthritis. Points are assigned across four domains: joint involvement (0-5 points), serology (0-3 points), acute phase reactants (0-1 point), and symptom duration (0-1 point). These criteria are intended for classification in clinical trials and epidemiological studies but guide diagnostic thinking in clinical practice. Joint involvement scoring in the 2010 criteria reflects the observation that polyarticular disease involving small joints carries the highest specificity for rheumatoid arthritis. One large joint involvement (shoulder, elbow, hip, knee, ankle) scores 0 points, while two to ten large joints score 1 point. One to three small joints (MCPs, PIPs, MTP 2-5, thumb IP, wrists) score 2 points, four to ten small joints score 3 points, and more than ten joints with at least one small joint scores the maximum 5 points. This weighting reflects the characteristic pattern of rheumatoid arthritis predominantly affecting small joints and the prognostic significance of polyarticular involvement. Serological testing provides crucial diagnostic and prognostic information in rheumatoid arthritis evaluation. Rheumatoid factor (RF), an IgM antibody directed against the Fc portion of IgG, is present in 70-80% of rheumatoid arthritis patients but lacks specificity, occurring in other autoimmune diseases, chronic infections, and a small percentage of healthy individuals (particularly elderly). Anti-cyclic citrullinated peptide (anti-CCP) antibodies, more accurately termed anti-citrullinated protein antibodies (ACPA), demonstrate superior specificity (approximately 95%) while maintaining reasonable sensitivity (approximately 70%). ACPA may be detected years before clinical disease onset and strongly predict erosive disease. In the 2010 criteria, negative RF and negative ACPA score 0 points, low-positive RF or low-positive ACPA scores 2 points, and high-positive RF or high-positive ACPA scores 3 points. Patients positive for both RF and ACPA ("double positive") have the highest risk of erosive disease. Acute phase reactants including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) reflect systemic inflammation and contribute to both diagnosis and disease activity assessment. Elevated CRP or ESR scores 1 point in the 2010 criteria. Symptom duration of 6 weeks or more also scores 1 point, reflecting the requirement for persistent rather than transient synovitis. Notably, normal acute phase reactants do not exclude rheumatoid arthritis, as a subset of patients have persistently normal values despite active synovitis. The presence of classical erosions on radiographs in a patient with synovitis compatible with rheumatoid arthritis also satisfies criteria regardless of point score, though this represents more advanced disease. Panel A: Flowchart of 2010 ACR/EULAR classification criteria showing entry criterion (clinical synovitis in at least one joint), scoring domains (joint involvement 0-5 points, serology 0-3 points, acute phase reactants 0-1 point, duration 0-1 point), and classification threshold (greater than or equal to 6 points). Panel B: Diagram illustrating joint scoring with small joints (MCPs, PIPs, wrists, MTPs) and large joints (shoulders, elbows, hips, knees, ankles) highlighted, with point assignments for different patterns. Panel C: Comparison of rheumatoid factor and anti-CCP antibodies showing sensitivity and specificity values, timing of appearance relative to clinical disease, and prognostic implications. Panel D: Laboratory interpretation guide showing typical findings in active rheumatoid arthritis (elevated ESR, elevated CRP, positive RF, positive anti-CCP, normocytic anemia) versus normal or alternative findings. --- ### VI. Imaging in Rheumatoid Arthritis Conventional radiography remains the foundational imaging modality for rheumatoid arthritis, providing assessment of structural damage that informs prognosis and treatment decisions. Radiographic findings reflect the cumulative effects of synovial inflammation on bone and cartilage. The earliest finding is soft tissue swelling around affected joints, though this is nonspecific. Periarticular osteopenia, demineralization of bone adjacent to inflamed joints, develops within weeks of disease onset. Joint space narrowing reflects cartilage loss from enzymatic degradation and impaired synthesis. Marginal erosions, the radiographic hallmark of rheumatoid arthritis, appear as discrete cortical defects at the bare areas of bone within the joint capsule but not covered by cartilage. Subluxation and deformity represent advanced structural damage. Radiographs of hands and feet are routinely obtained at baseline and periodically to monitor for progression. Erosions in rheumatoid arthritis demonstrate characteristic features distinguishing them from other causes of bony destruction. They occur at marginal locations, the bare areas where synovium directly contacts bone without intervening cartilage. The typical appearance is a sharply demarcated defect with irregular margins, sometimes described as "rat bite" erosions. The MCP joints, particularly the second and third, PIP joints, and MTP joints (especially the fifth) are common erosion sites. Carpal bones, particularly the ulnar styloid, are frequently affected. Erosions indicate poor prognosis and typically warrant intensification of disease-modifying therapy. Modern treatment strategies aim to prevent erosion development by achieving early disease control. Musculoskeletal ultrasound has emerged as a valuable complement to clinical examination and radiography in rheumatoid arthritis assessment. Ultrasound detects synovitis as hypoechoic synovial thickening and effusion, often identifying inflammation in joints that appear clinically normal. Power Doppler signal indicates increased vascularity correlating with active inflammation and predicting structural progression. Ultrasound can detect erosions earlier than radiography due to its ability to directly visualize bone surfaces without superimposition. Additional advantages include lack of ionizing radiation, portability, relatively low cost, and ability to guide diagnostic and therapeutic joint injections. Limitations include operator dependence and inability to assess some anatomic regions. Magnetic resonance imaging (MRI) provides the most sensitive detection of early inflammatory and destructive changes in rheumatoid arthritis. Synovitis appears as enhancing tissue on gadolinium-enhanced sequences. Bone marrow edema, visible as increased signal on fluid-sensitive sequences, represents pre-erosive inflammation within bone and strongly predicts subsequent erosion development at that site. MRI detects erosions earlier and with greater sensitivity than radiography. Tenosynovitis involving flexor and extensor tendons is readily visualized. The OMERACT RAMRIS (Outcome Measures in Rheumatology Rheumatoid Arthritis MRI Scoring System) provides standardized assessment of synovitis, bone marrow edema, and erosions. Despite its sensitivity, MRI remains a complementary tool rather than routine monitoring due to cost and availability constraints. Panel A: Plain radiograph of rheumatoid hands showing the progressive findings: periarticular osteopenia around MCP joints, joint space narrowing, and marginal erosions at MCP heads and ulnar styloid, with each finding labeled. Panel B: Close-up radiographic image of marginal erosion showing the characteristic "rat bite" appearance at the bare area of an MCP joint, with anatomical diagram explaining why erosions occur at these sites. Panel C: Ultrasound images demonstrating synovitis (hypoechoic thickening) and power Doppler signal indicating active inflammation at the wrist, with comparison to normal ultrasound appearance. Panel D: MRI sequences showing synovitis enhancement on post-contrast T1, bone marrow edema on STIR/T2, and early erosion, illustrating MRI's superior sensitivity for detecting pre-radiographic changes. --- ### VII. Disease Activity Assessment Standardized composite measures of disease activity enable objective assessment of rheumatoid arthritis status and guide treatment decisions within the treat-to-target paradigm. The Disease Activity Score using 28 joints (DAS28) combines tender joint count (0-28 joints), swollen joint count (0-28 joints), acute phase reactant (ESR or CRP), and patient global assessment of disease activity on a visual analog scale. The mathematical formula produces a continuous score that is categorized into disease activity states. The Clinical Disease Activity Index (CDAI) sums tender joint count, swollen joint count, patient global assessment, and physician global assessment without laboratory values, enabling immediate calculation during clinic visits. The Simplified Disease Activity Index (SDAI) adds CRP to the CDAI components. Routine assessment at each visit allows tracking of disease trajectory and response to treatment. Interpretation of DAS28 scores guides therapeutic decision-making according to established thresholds. A DAS28 score below 2.6 indicates remission, the primary treatment target. Scores between 2.6 and 3.2 represent low disease activity, an acceptable alternative target when remission is not achievable. Moderate disease activity corresponds to scores between 3.2 and 5.1, while high disease activity is indicated by scores above 5.1. Patients not achieving low disease activity or remission despite adequate treatment duration warrant therapy modification. The DAS28-CRP and DAS28-ESR versions may yield different absolute values, with DAS28-CRP typically producing lower scores, so consistent use of one version is recommended for serial monitoring. The treat-to-target strategy, now standard of care in rheumatoid arthritis management, involves setting a specific therapeutic target and adjusting treatment until that target is achieved and maintained. The primary target is remission, defined by DAS28 below 2.6 or by more stringent ACR/EULAR Boolean remission criteria requiring tender joint count of 1 or fewer, swollen joint count of 1 or fewer, CRP of 1 mg/dL or less, and patient global assessment of 1 or less on a 0-10 scale. Low disease activity serves as an alternative target when remission is not feasible, particularly in patients with long-standing disease or irreversible damage. Treatment should be adjusted every 3 months until the target is reached, with more frequent assessment during active disease. This approach has been demonstrated to improve outcomes compared to conventional care. Functional assessment and patient-reported outcomes complement disease activity measures in comprehensively evaluating rheumatoid arthritis impact. The Health Assessment Questionnaire Disability Index (HAQ-DI) quantifies functional impairment across eight categories of daily activities. Radiographic progression, assessed using the Sharp/van der Heijde scoring system or similar methods, provides objective evidence of structural damage that predicts long-term disability. Quality of life instruments including the SF-36 and EQ-5D capture broader impacts on physical, emotional, and social well-being. Work productivity measures assess the substantial indirect costs of rheumatoid arthritis. Integration of clinical disease activity, patient-reported outcomes, and structural assessment provides a comprehensive picture of disease status and treatment effectiveness. Panel A: DAS28 calculation diagram showing the four components (tender joint count, swollen joint count, ESR or CRP, patient global) and the formula, with visual representation of the 28-joint assessment (bilateral shoulders, elbows, wrists, MCPs, PIPs, knees). Panel B: Disease activity thresholds graph showing remission (less than 2.6), low disease activity (2.6-3.2), moderate disease activity (3.2-5.1), and high disease activity (greater than 5.1) zones, with treatment implications for each. Panel C: Treat-to-target algorithm flowchart showing assessment of disease activity, decision points based on achieving target, and treatment adjustment recommendations, emphasizing the 3-month assessment cycle. Panel D: ACR/EULAR Boolean remission criteria checklist showing the four requirements (tender joint count less than or equal to 1, swollen joint count less than or equal to 1, CRP less than or equal to 1 mg/dL, patient global less than or equal to 1) that must all be met. --- ### VIII. Disease-Modifying Antirheumatic Drugs Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) form the foundation of rheumatoid arthritis treatment, with methotrexate serving as the anchor drug for most patients. Methotrexate, a folate antagonist with additional immunomodulatory effects including adenosine release, is typically initiated at 7.5-15 mg weekly with titration up to 25 mg weekly as tolerated and indicated. Folic acid supplementation at 1 mg daily reduces gastrointestinal and mucosal side effects without diminishing efficacy. Common adverse effects include nausea, fatigue, mouth sores, and transaminase elevation; more serious toxicities include bone marrow suppression and rarely methotrexate pneumonitis. Methotrexate is absolutely contraindicated in pregnancy due to teratogenicity and abortifacient effects. Monitoring includes complete blood count and liver function tests every 8-12 weeks after stable dosing is achieved. Subcutaneous administration may improve bioavailability and reduce gastrointestinal side effects compared to oral dosing. Additional csDMARDs provide alternatives or additions to methotrexate in rheumatoid arthritis treatment. Hydroxychloroquine, an antimalarial with immunomodulatory properties, is used for mild disease or in combination regimens; it requires annual ophthalmologic monitoring for retinal toxicity after 5 years of use. Sulfasalazine, combining anti-inflammatory and immunomodulatory effects, serves as an alternative first-line agent or in combination with methotrexate and hydroxychloroquine ("triple therapy"). Leflunomide, a pyrimidine synthesis inhibitor, provides efficacy comparable to methotrexate and may be used as an alternative or in combination. These agents may be combined in various regimens when methotrexate monotherapy provides insufficient disease control. Biologic disease-modifying antirheumatic drugs (bDMARDs) target specific components of the immune response and have transformed outcomes for patients with inadequate response to conventional therapy. Tumor necrosis factor inhibitors (adalimumab, etanercept, infliximab, certolizumab, golimumab) were the first biologic class developed for rheumatoid arthritis and remain widely used; they are administered subcutaneously or intravenously and substantially reduce inflammation and structural progression. Interleukin-6 inhibitors (tocilizumab, sarilumab) block the IL-6 receptor, reducing both local and systemic inflammation. Abatacept, a CTLA-4-Ig fusion protein, inhibits T cell costimulation by blocking the CD80/86-CD28 interaction. Rituximab, an anti-CD20 monoclonal antibody, depletes B cells and is particularly useful in seropositive disease. Biosimilars of several TNF inhibitors are available at reduced cost with equivalent efficacy and safety. Targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), specifically Janus kinase (JAK) inhibitors, represent the newest class of rheumatoid arthritis therapies. Tofacitinib, baricitinib, and upadacitinib are orally administered small molecules that inhibit JAK enzymes involved in intracellular cytokine signaling. They provide efficacy comparable to biologic agents with the convenience of oral administration. Safety considerations include increased risk of herpes zoster, potential for lipid elevations, and emerging concerns about venous thromboembolism, major adverse cardiovascular events, and malignancy risk compared to TNF inhibitors in high-risk patients. Current guidelines suggest preferential use of TNF inhibitors over JAK inhibitors in patients with cardiovascular risk factors, though JAK inhibitors remain valuable options for many patients. Panel A: Overview of DMARD classes showing csDMARDs (methotrexate, hydroxychloroquine, sulfasalazine, leflunomide), bDMARDs by target (TNF inhibitors, IL-6 inhibitors, T cell costimulation blocker, B cell depleting agent), and tsDMARDs (JAK inhibitors), with route of administration and dosing intervals indicated. Panel B: Methotrexate mechanism and monitoring diagram showing folate pathway inhibition and adenosine release mechanisms, common side effects, and monitoring schedule (CBC, LFTs every 8-12 weeks). Panel C: Biologic drug mechanisms illustrated at the cellular level showing TNF inhibitors binding TNF-alpha, tocilizumab blocking IL-6 receptor, abatacept preventing T cell costimulation, and rituximab depleting CD20+ B cells. Panel D: JAK-STAT signaling pathway diagram showing where JAK inhibitors act, cytokine receptors using this pathway, and downstream effects on gene transcription. --- ### IX. Treatment Strategy and Approach The modern treatment paradigm for rheumatoid arthritis emphasizes early, aggressive intervention based on evidence that a "window of opportunity" exists during which achieving disease control prevents irreversible joint damage and improves long-term outcomes. Treatment should be initiated within 3 months of symptom onset, and ideally within 12 weeks of diagnosis. Methotrexate is the first-line DMARD for most patients unless contraindicated, with rapid escalation to effective doses. Short-term glucocorticoids provide bridging therapy during the weeks to months required for DMARDs to achieve full effect. The treat-to-target approach guides ongoing management with treatment adjustment every 3 months until remission or low disease activity is achieved. Step-up therapy proceeds through a logical sequence when initial treatment provides inadequate disease control. Step 1 involves methotrexate monotherapy, optimizing dose and route (subcutaneous if oral is inadequate or not tolerated). Step 2 adds or substitutes another csDMARD, with options including triple therapy (methotrexate, sulfasalazine, hydroxychloroquine), methotrexate plus leflunomide, or switching to leflunomide monotherapy. Step 3 adds a biologic DMARD (typically a TNF inhibitor as first-line biologic) or JAK inhibitor to methotrexate background therapy; methotrexate enhances efficacy of most biologics and reduces immunogenicity. Step 4 involves switching to an alternative biologic, often changing mechanism of action (for example, from TNF inhibitor to IL-6 inhibitor, abatacept, or rituximab). This algorithmic approach maximizes the probability of achieving disease control while allowing individualization based on patient factors. Adjunctive therapies address symptoms and complications while DMARDs work to control underlying disease. Glucocorticoids provide rapid anti-inflammatory effect and are used as bridging therapy at treatment initiation, during DMARD changes, and for disease flares. The goal is to minimize glucocorticoid exposure by limiting dose (prednisone 7.5 mg or less daily if ongoing use required) and duration, given cumulative toxicities including osteoporosis, diabetes, cardiovascular risk, and infection susceptibility. Nonsteroidal anti-inflammatory drugs (NSAIDs) provide symptomatic relief but do not prevent structural damage and carry their own toxicity profiles. Intra-articular corticosteroid injection effectively manages single-joint flares when systemic disease is otherwise controlled. Poor prognostic factors identify patients who may benefit from more aggressive initial therapy, including early biologic introduction. High disease activity at presentation, reflected in multiple swollen joints, markedly elevated acute phase reactants, or high composite disease activity scores, predicts worse outcomes. Early erosions or rapid radiographic progression indicate aggressive disease requiring intensified treatment. Seropositivity for both rheumatoid factor and anti-CCP antibodies, particularly at high titers, strongly predicts erosive disease. Functional limitation at baseline suggests the disease is already impacting the patient's life significantly. The presence of extra-articular manifestations indicates systemic disease. These factors may justify moving more rapidly through the treatment algorithm or starting combination therapy initially. Panel A: Timeline illustrating the "window of opportunity" concept, showing optimal intervention within 3 months of symptom onset, with progressive structural damage and declining probability of remission as treatment is delayed. Panel B: Step-up treatment algorithm flowchart showing progression from methotrexate monotherapy through csDMARD combination to biologic or JAK inhibitor addition, with assessment timepoints and decision criteria at each step. Panel C: Glucocorticoid bridging therapy diagram showing high initial doses for rapid symptom control with taper as DMARD effect develops, target of minimal or no glucocorticoid use by 6 months. Panel D: Poor prognostic factors checklist including high disease activity, early erosions, RF and ACPA positivity (especially double-positive at high titers), functional limitation, and extra-articular disease, with treatment implications. --- ### X. Monitoring, Complications, and Prognosis Drug monitoring protocols ensure safe use of immunosuppressive therapies while detecting adverse effects early. For methotrexate, monitoring includes complete blood count, liver function tests, and creatinine every 8-12 weeks once stable dosing is achieved, with more frequent monitoring during dose escalation. Biologic agents require screening for latent tuberculosis (tuberculin skin test or interferon-gamma release assay) before initiation, with treatment of latent infection before starting therapy. Hepatitis B serologies (HBsAg, anti-HBc, anti-HBs) are checked before biologic or JAK inhibitor therapy, as reactivation can occur with immunosuppression. Hepatitis C screening is also performed. JAK inhibitors require lipid monitoring given their propensity to raise cholesterol levels. Hydroxychloroquine necessitates baseline and annual ophthalmologic examination after 5 years of use to detect early retinal toxicity. Infection risk is increased in rheumatoid arthritis due to both the underlying immune dysregulation and immunosuppressive therapy. Patients should receive vaccinations before initiating immunosuppression when possible, including pneumococcal (both conjugate and polysaccharide), annual influenza, and herpes zoster (recombinant preferred) vaccines. Live vaccines are contraindicated during biologic or JAK inhibitor therapy. Patients should be educated about infection signs and symptoms and instructed to hold immunosuppressive therapy and seek medical attention if serious infection is suspected. Opportunistic infections including tuberculosis (reactivation with TNF inhibitors) and herpes zoster (particularly with JAK inhibitors) require heightened vigilance. Temporary discontinuation of biologics is typically recommended perioperatively given surgical infection risk. Comorbidity management addresses the systemic complications and treatment-related conditions that contribute to morbidity and mortality. Cardiovascular risk management is paramount given accelerated atherosclerosis; aggressive treatment of traditional risk factors combined with rheumatoid arthritis disease control (which reduces inflammatory contribution) is recommended. Osteoporosis prevention and treatment addresses the bone loss resulting from inflammation, glucocorticoid use, and immobility. Malignancy screening follows age-appropriate guidelines, with awareness that lymphoma risk is increased in rheumatoid arthritis (particularly in severe, poorly controlled disease) though not clearly further increased by most therapies. Depression and anxiety are common and should be screened for and treated. Prognosis in rheumatoid arthritis has been transformed by modern treatment approaches, with most patients now achieving good disease control and maintaining function when treated early and appropriately. The treat-to-target approach significantly improves outcomes compared to conventional care. Remission is achievable in a substantial proportion of patients, particularly those treated early. Radiographic progression can be halted or dramatically slowed with effective therapy. Work disability has decreased substantially in the biologic era. Mortality, historically elevated compared to the general population primarily due to cardiovascular disease, appears to be improving with better disease control. However, outcomes vary, and some patients continue to have refractory disease despite multiple therapeutic attempts, highlighting the need for continued research and development of new therapies. Panel A: Drug monitoring table showing required baseline and ongoing tests for methotrexate (CBC, LFTs, creatinine), biologics (TB screening, hepatitis serologies), JAK inhibitors (lipids, CBC), and hydroxychloroquine (ophthalmologic exam), with monitoring frequencies. Panel B: Vaccination recommendations for rheumatoid arthritis patients showing timing relative to immunosuppression, vaccines to administer (pneumococcal, influenza, zoster), and live vaccines to avoid. Panel C: Comorbidity management diagram showing cardiovascular risk (lipid management, disease control), osteoporosis (DXA screening, calcium/vitamin D, bisphosphonates), infection prevention (vaccines, patient education), and depression screening, with intervention strategies. Panel D: Prognosis comparison showing outcomes before and after modern DMARD era, with improvements in remission rates, work disability, radiographic progression, and mortality when treat-to-target approach is employed. --- ## Summary - Rheumatoid arthritis is a chronic systemic autoimmune disease targeting the synovium, causing symmetric inflammatory polyarthritis predominantly affecting small joints - Risk factors include HLA-DR4 (shared epitope), female sex, and cigarette smoking, which is the strongest modifiable environmental risk factor - Clinical presentation features morning stiffness exceeding 60 minutes, symmetric MCP/PIP/wrist involvement, and characteristic sparing of DIPs and thoracolumbar spine - Extra-articular manifestations include rheumatoid nodules, interstitial lung disease, accelerated cardiovascular disease, and Felty syndrome - Diagnosis uses 2010 ACR/EULAR criteria incorporating joint involvement, serology (RF, anti-CCP), acute phase reactants, and symptom duration - Imaging reveals marginal erosions, periarticular osteopenia, and joint space narrowing on radiographs; MRI and ultrasound detect earlier changes - Treatment follows treat-to-target strategy with methotrexate as first-line DMARD, adding biologics or JAK inhibitors for inadequate response - Disease activity monitoring using DAS28, CDAI, or SDAI guides treatment adjustments toward remission or low disease activity targets - Modern treatment has transformed prognosis, with most patients achieving disease control when treated early and appropriately --- ## Key Terms | Term | Definition | |------|------------| | Rheumatoid factor | IgM autoantibody directed against the Fc portion of IgG; present in 70-80% of RA patients | | Anti-CCP (ACPA) | Antibodies against citrullinated proteins; highly specific for RA and predict erosive disease | | Pannus | Invasive, vascularized synovial tissue that causes cartilage and bone destruction | | DMARD | Disease-modifying antirheumatic drug; prevents structural damage unlike symptomatic therapies | | DAS28 | Disease Activity Score using 28 joints; composite measure guiding treat-to-target approach | | Swan neck deformity | PIP hyperextension with DIP flexion due to volar plate laxity and lateral band displacement | | Boutonniere deformity | PIP flexion with DIP hyperextension due to central slip rupture | | Treat-to-target | Treatment strategy adjusting therapy to achieve specific disease activity target (remission or low disease activity) | | Shared epitope | Conserved amino acid sequence in HLA-DR molecules associated with RA susceptibility | | Marginal erosion | Discrete cortical bone defect at bare areas within the joint; radiographic hallmark of RA | --- *This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*